INTRODUCTION {#S1}
============

Exposure to pathogens leads to activation of naive CD8^+^ T cells, which then undergo clonal expansion. After clearance of infections, most of the antigen-specific CD8^+^ T cells undergo apoptosis during contraction (effector-to-memory transition) phase ([@R50]; [@R80]; [@R109]). However, some antigen-specific CD8^+^ T cells survive and differentiate into memory CD8^+^ T cells, which are metabolically quiescent. Memory CD8^+^ T cells, which include both effector memory and central memory T cells, are formed in the secondary lymphoid organs such as spleen and lymph nodes ([@R49]). Upon re-activation, effector memory CD8^+^ T cells can rapidly expand into effector CD8^+^ T cells and mount potent cytotoxic functions ([@R90]; [@R64]). However, the processes that specifically regulate differentiation of effector memory CD8^+^ T cells remain unclear.

Whereas activated effector CD8^+^ T cells depend on glycolysis for their metabolic needs ([@R7]), memory CD8^+^ T cells use long-chain fatty acid oxidation to generate energy ([@R75]). Fatty acid metabolism takes place in mitochondria, where they undergo β-oxidation to generate energy in the form of ATP. However, the molecules that regulate long-chain fatty acid oxidation in memory CD8^+^ T cells have not been identified.

We and others have shown that deletion of NIX, a Bcl-2-family protein on the mitochondrial outer membrane ([@R67]), impairs the ability of autophagosomes to degrade mitochondria in reticulocytes via mitophagy ([@R92]; [@R94]). Failure to clear dysfunctional mitochondria in the absence of NIX leads to accumulation of mitochondrial superoxide in natural killer (NK) memory cells ([@R76]). We have previously shown that mitochondrial superoxide is detrimental to immunological memory in B cells ([@R22]). The extent of superoxide production depends on mitochondrial quality regulated by mitophagy, wherein dysfunctional mitochondria are degraded via the autophagolysosomal pathway. Degraded mitochondria are later replaced by new functional mitochondria through mitochondrial biogenesis, which is regulated by mitochondrial transcription factor A (TFAM) ([@R4]; [@R47]; [@R101]). Although we and others have previously shown that autophagy is critical for formation and survival of memory B and T cells in mice ([@R22], [@R23]; [@R72]; [@R81]; [@R111]), the molecular mechanisms regulating formation of effector memory in CD8^+^ T cells remain unknown.

In this study, using a T cell-specific NIX-deficient mouse model, we show that NIX-dependent mitophagy plays a protective role in differentiation of virus-specific effector memory CD8^+^ T cells by modulating long-chain and short/branched-chain fatty acid oxidation.

RESULTS {#S2}
=======

NIX Is Critical for Formation of Effector Memory in Ova-Specific CD8^+^ T Cells {#S3}
-------------------------------------------------------------------------------

To explore the role of NIX in effector memory CD8^+^ T cell differentiation, we quantified *Nix* expression in CD8^+^ T cells after immunization of wild-type (WT) mice with vesicular stomatitis virus co-expressing ovalbumin (VSV-Ova). While *Nix* was downregulated in Ova-specific CD8^+^ T cells during primary response on day 6 post-immunization (p.i.), it was upregulated from day 10 p.i. ([Figure 1A](#F1){ref-type="fig"}), the onset of contraction phase (effector-to-memory transition phase) in CD8^+^ T cells ([@R111]). The expression of *Nix* continued to further increase during the course of immunological memory formation in Ova-specific CD8^+^ T cells ([Figure 1A](#F1){ref-type="fig"}), suggesting that NIX potentially plays a role in CD8^+^ T cell memory formation.

IL-15 plays a critical role in immunological memory formation ([@R93]; [@R112]), but its mechanism is unclear. We found that *Nix* expression was upregulated in Ova-specific CD8^+^ T cells within 24 h of IL-15 addition ([Figure 1B](#F1){ref-type="fig"}). We further examined whether the initial downregulation in *Nix* expression during primary response ([Figure 1A](#F1){ref-type="fig"}) was mediated through TCR signaling. Upon CD3 stimulation, Ova-specific CD8^+^ T cells downregulated *Nix*; however, *Nix* expression was upregulated after subsequent addition of IL-15 ([Figure 1C](#F1){ref-type="fig"}). Consistent with increased *Nix* expression during the contraction phase ([Figure 1A](#F1){ref-type="fig"}), we observed concomitant increase in IL-15 receptor α (*Il15ra*) expression in Ova-specific CD8^+^ T cells during the contraction phase in VSV-Ova-immunized WT mice ([Figure 1D](#F1){ref-type="fig"}). These data suggest that TCR signaling downregulates *Nix* expression during the primary response, while IL-15 signaling might contribute to the upregulation of *Nix* expression during memory formation in antigen-specific CD8^+^ T cells.

To investigate the role of NIX in immunological memory formation, we generated mice with T cell-specific deletion of *Nix* (*Lck*^cre^ × *Nix*^f/f^ mice, denoted T/NIX^−/−^). The development of double-negative (DN; CD44^−^CD25^−^) or double-positive (DP; CD44^+^CD25^+^) T cell populations were similar between WT and T/NIX−/− mice ([Figures S1A](#SD1){ref-type="supplementary-material"} and [S1B](#SD1){ref-type="supplementary-material"}). Within the DN population, DN1 (CD44^+^CD25^−^), DN2 (CD44^+^CD25^+^), DN3 (CD44^−^CD25^+^), and DN4 (CD44^−^CD25^−^) cells were also similar between WT and T/NIX^−/−^ mice ([Figures S1C](#SD1){ref-type="supplementary-material"} and [S1D](#SD1){ref-type="supplementary-material"}). Frequency of mature CD4^+^ and CD8^+^ T cells, naive, central memory and effector CD8^+^ T cells were also comparable between the WT and T/NIX^−/−^ mice ([Figures S1E](#SD1){ref-type="supplementary-material"}-[S1H](#SD1){ref-type="supplementary-material"}). These data suggest that NIX deficiency in T cells did not alter T cell development and migration to periphery.

CD43 (1B11) is expressed on activated but not memory CD8^+^ T cells ([@R36]; [@R41]; [@R77]). Therefore, we used CD3^+^CD8^+^CD62L^−^ CD44^+^CD43^−^Ova_tetramer^+^ cells as Ova-specific effector memory CD8^+^ T cells (Ova-EM), CD3^+^CD8^+^CD62L^+^CD44^+^ CD43^−^Ova_tetramer^+^ cells as Ova-specific central memory CD8^+^ T cells (Ova-CM), and CD3^+^CD8^+^CD62L^−^CD44^+^ CD43^+^Ova_tetramer^+^ cells as Ova-specific activated CD8^+^ T cells (Ova-activated) in our experiments. In addition, we used CD3^+^CD8^+^CD62L^−^CD44^+^CD127^+^Ova_tetramer^+^ cells on day 10 p.i. as Ova-specific CD8^+^ memory precursor effector cells (Ova-CD8^+^ MPECs); which exhibited no significant alteration in their expression of KLRG1, a marker of terminal differentiation ([@R48]; [@R106]; [@R115]), between WT and T/NIX^−/−^ mice ([Figure S2A](#SD1){ref-type="supplementary-material"}).

We next immunized WT and T/NIX^−/−^ mice with VSV-Ova, which was cleared by both the hosts before the contraction phase ([Figure S2B](#SD1){ref-type="supplementary-material"}), and measured the frequency of Ova-EM and Ova-CM 30 days p.i. Interestingly, we observed significantly reduced frequency of Ova-EM in T/NIX^−/−^ mice ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}) but not Ova-CM ([Figure S2C](#SD1){ref-type="supplementary-material"}). When additional T cell memory phenotypic markers, KLRG1 and CD127 ([@R11]; [@R48]), were included, CD127^+^KLRG1^−^ Ova-EM was also impaired in T/NIX^−/−^ mice ([Figures S2D](#SD1){ref-type="supplementary-material"} and [S2E](#SD1){ref-type="supplementary-material"}). Some studies suggest that T cell memory is promoted by CXCR5 and TCF7 but inhibited by TIM3 ([@R5]; [@R14]; [@R59]; [@R89]; [@R114]). We found that CXCR5^+^TIM3^−^TCF7^+^ Ova-EM cells were significantly impaired in T/NIX^−/−^ mice 30 days p.i. ([Figures S2F](#SD1){ref-type="supplementary-material"} and [S2G](#SD1){ref-type="supplementary-material"}). To test if this impairment was CD8^+^ T cell intrinsic, we adoptively transferred CD8^+^ T cells using the experimental setup as described ([Figure 1G](#F1){ref-type="fig"}). We found that the formation of effector memory was defective in host CD45.2^+^ T/NIX^−/−^ CD8^+^ T cells compared with donor CD45.1^+^ WT CD8^+^ T cells ([Figure 1H](#F1){ref-type="fig"}), suggesting that the impairment in CD8^+^ T cell effector memory formation due to NIX ablation was intrinsic in nature. Moreover, frequency of Ova-activated CD8^+^ T cells did not change in T/NIX^−/−^ mice during the peak primary response ([@R26]; [Figure S2H](#SD1){ref-type="supplementary-material"}), and CD8^+^ T cells from naive WT and T/NIX^−/−^ mice proliferated to the same extent upon CD3/CD28 stimulation ([Figure S2I](#SD1){ref-type="supplementary-material"}), suggesting that reduced Ova-EM frequency was not due to altered primary response. Furthermore, BNIP3, a NIX homolog, was not required for effector memory formation in Ova-specific CD8^+^ T cells ([Figures S2J](#SD1){ref-type="supplementary-material"} and [S2K](#SD1){ref-type="supplementary-material"}), although there was an overall reduction in *Bnip3* expression in Ova-specific CD8^+^ T cells during VSV-Ova infection ([Figure S2L](#SD1){ref-type="supplementary-material"}), likely due to *Bnip3* downregulation during central memory formation ([Figure S2M](#SD1){ref-type="supplementary-material"}). Pink1 and Parkin (Park2), which also control mitophagy in mammalian cells ([@R34]; [@R46]), were not significantly upregulated during T cell memory formation either ([Figure S2N](#SD1){ref-type="supplementary-material"}). These data suggest a unique role for NIX in CD8^+^ T cell effector memory formation.

Next, we found that CD8^+^ T cell effector memory formation was impaired between days 10 and 20 p.i. in T/NIX^−/−^ mice ([Figures 1I](#F1){ref-type="fig"} and [S2O](#SD1){ref-type="supplementary-material"}), suggesting that NIX deficiency during the contraction phase was the causative factor. Caspase-3 (Casp3) can mediate apoptosis in virus-specific effector T cells during the contraction phase ([@R33]; [@R53]; [@R88]; [@R95]). We found that *Casp3* expression was increased in T/NIX^−/−^ Ova-CD8^+^ MPECs but not in fully formed T/NIX^−/−^ Ova-EM ([Figure S2P](#SD1){ref-type="supplementary-material"}). Moreover, apoptosis during the contraction phase was increased in T/NIX^−/−^ Ova-CD8^+^ MPECs but not Ova-EM, as indicated by annexin V staining ([Figures S2Q](#SD1){ref-type="supplementary-material"} and [S2R](#SD1){ref-type="supplementary-material"}). These data suggest that the defective CD8^+^ T cell effector memory formation in T/NIX^−/−^ mice was caused by a loss of Ova-CD8^+^ MPECs but not due to an increased apoptosis in newly formed Ova-EM. This critical requirement of NIX during the contraction phase was consistent with *Nix* upregulation in Ova-CD8^+^ MPECs on day 10 p.i., followed by a significant upregulation in Ova-EM by day 30 p.i. in WT mice ([Figure 1J](#F1){ref-type="fig"}). In contrast to Ova-EM, NIX expression did not change in Ova-CM, consistent with no change in Ova-CM differentiation despite absence of NIX ([Figure S2C](#SD1){ref-type="supplementary-material"}). We also quantified expression of *Foxo1* and *Tcf7*, transcription factors critical for CD8^+^ T cell memory formation ([@R61]; [@R116]; [@R40]), in Ova-CD8^+^ MPECs ([@R27]; [@R54]). Their expression was significantly reduced in T/NIX^−/−^ Ova-CD8^+^ MPECs ([Figure 1K](#F1){ref-type="fig"}). In addition, expression of *Blimp-1*, a transcription factor inhibiting CD8^+^ T cell memory formation ([@R87]), was upregulated in T/NIX^−/−^ Ova-CD8^+^ MPECs ([Figure S2S](#SD1){ref-type="supplementary-material"}). Likewise, *Foxo1* and *Tcf7* were significantly reduced ([Figure 1L](#F1){ref-type="fig"}) and *Blimp-1* was upregulated ([Figure S2T](#SD1){ref-type="supplementary-material"}) in T/NIX^−/−^ Ova-EM 30 days p.i. We also studied formation of Ova-EM *in vitro* in the presence of IL-15 ([@R16]; [@R75]; [@R101], [@R102]), with effector-to-memory transition phase falling between day 3 and day 7 post-activation ([Figure S2U](#SD1){ref-type="supplementary-material"}), and confirmed that the absence of NIX significantly impaired Ova-EM formation ([Figure 1M](#F1){ref-type="fig"}). Together, our data suggest that NIX is critical for optimal generation of effector memory in antigen-specific CD8^+^ T cells during the contraction phase.

Impaired Effector Memory Formation in Antigen-Specific CD8^+^ T Cells Leads to a Defective Recall Response {#S4}
----------------------------------------------------------------------------------------------------------

We next transferred equal numbers of CD45.2^+^ Ova-EM (from WT or T/NIX^−/−^ mice) into naive CD45.1^+^ hosts, which were subsequently challenged with VSV-Ova. Forty-eight hours later, memory recall response of CD45.2^+^ Ova-EM was studied ([@R21]; [@R26]). Upon re-activation of Ova-EM by VSV-Ova, *Nix* expression was downregulated in CD45.2^+^ WT CD8^+^ T cells ([Figure S3A](#SD1){ref-type="supplementary-material"}), consistent with our earlier data ([Figures 1A](#F1){ref-type="fig"}, [1C](#F1){ref-type="fig"}, and [1J](#F1){ref-type="fig"}) demonstrating that CD8^+^ T cell activation downregulates *Nix* expression. We then investigated if limited effector memory formation in T/NIX^−/−^ CD8^+^ T cells would cause a defective memory recall response. Recipients of *in vivo* generated T/NIX^−/−^ Ova-EM showed a reduced recall response ([Figure 2A](#F2){ref-type="fig"}), which was verified by ELISA ([Figure 2B](#F2){ref-type="fig"}) and intracellular staining ([Figures 2C](#F2){ref-type="fig"}, [2D](#F2){ref-type="fig"}, and [S3B](#SD1){ref-type="supplementary-material"}) for IFN-γ and IL-2. In addition, T/NIX^−/−^ Ova-EM proliferated significantly lesser than their WT counterparts upon VSV-Ova re-challenge ([Figure 2E](#F2){ref-type="fig"}). Consistent with defective memory recall response in Ova-EM developed *in vivo*, we also observed an impaired memory recall response by T/NIX^−/−^ Ova-EM generated *in vitro* ([Figures 2F](#F2){ref-type="fig"}-[2I](#F2){ref-type="fig"} and [S3C](#SD1){ref-type="supplementary-material"}). Proliferation upon secondary challenge has been shown to depend on mitochondrial spare respiratory capacity (SRC) in memory T cells ([@R102]). Hence, we performed extracellular flux analysis (Seahorse assay) to measure mitochondrial SRC and found that T/NIX^−/−^ Ova-EM had significantly lesser SRC ([Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}). These data indicate that defective effector memory formation in antigen-specific T/NIX^−/−^ CD8^+^ T cells resulted in a defective recall response, likely through impairment in mitochondrial SRC.

Absence of NIX Causes Mitochondrial Accumulation during Effector Memory Formation in Antigen-Specific CD8^+^ T Cells {#S5}
--------------------------------------------------------------------------------------------------------------------

We next examined the molecular mechanism behind impaired CD8^+^T cell effector memory formation in T/NIX^−/−^ mice. Because NIX is involved in mitochondrial clearance in red blood cells ([@R92]; [@R94]), we quantified total mitochondria in Ova-EM formed *in vivo* after VSV-Ova immunization. T/NIX^−/−^ Ova-EM showed significantly more mitochondria than WT controls on day 30 p.i. ([Figure 3A](#F3){ref-type="fig"}), which we verified via immunostaining of mitochondrial COX IV ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). Mitochondrial levels in naive CD8^+^ T cells were comparable between WT and T/NIX^−/−^ mice ([Figures S4A](#SD1){ref-type="supplementary-material"}-[S4D](#SD1){ref-type="supplementary-material"}), suggesting that mitochondrial accumulation due to deletion of NIX occurred during effector memory formation, rather than naive CD8^+^ T cell stage.

To determine if mitochondrial accumulation in T/NIX^−/−^ Ova-EM occurred because of impaired mitophagy, we performed co-localization analysis of stained mitochondria and autophagosomes in Ova-EM generated *in vivo* on day 30 p.i. Mitophagy in Ova-EM was significantly decreased in T/NIX^−/−^ mice ([Figures 3D](#F3){ref-type="fig"} and [S4E](#SD1){ref-type="supplementary-material"}), but not because of altered basal autophagy, as shown by similar levels of LC3 and autophagic vacuoles in WT and T/NIX^−/−^ Ova-EM ([Figures S4F](#SD1){ref-type="supplementary-material"} and [S4G](#SD1){ref-type="supplementary-material"}), suggesting that reduced mitophagy in T/NIX^−/−^ Ova-EM stemmed from an inability of available autophagosomes to degrade mitochondria. Interestingly, there were no significant changes in the level of mitochondria ([Figures S4A](#SD1){ref-type="supplementary-material"}-[S4D](#SD1){ref-type="supplementary-material"}) and mitophagy ([Figure S4E](#SD1){ref-type="supplementary-material"}) in Ova-CM in absence of NIX. We also observed significantly higher levels of mitophagy in WT Ova-EM compared with WT naive CD8^+^ T cells, which reversed upon deletion of NIX ([Figure S4E](#SD1){ref-type="supplementary-material"}). These data suggest that NIX regulates mitophagy during CD8^+^ T cell effector memory formation, but not at naive CD8^+^ T cell stage. As expected, deletion of NIX did not alter basal autophagy in naive CD8^+^ T cells or Ova-EM, although Ova-EM showed significantly more basal autophagy than naive CD8^+^ T cells ([Figures S4F](#SD1){ref-type="supplementary-material"} and [S4G](#SD1){ref-type="supplementary-material"}).

Mitochondrial accumulation in T/NIX^−/−^ Ova-EM could also be due to increased mitochondrial biogenesis, which is regulated by TFAM ([@R4]; [@R47]; [@R101]) in mammalian cells. We found no significant difference in *Tfam* gene expression ([Figure 3E](#F3){ref-type="fig"}) or TFAM protein level ([Figure 3F](#F3){ref-type="fig"}) between WT and T/NIX^−/−^ mice, indicating that mitochondrial biogenesis did not play a role in mitochondrial accumulation in T/NIX^−/−^ Ova-EM.

Deletion of NIX Results in Elevation of Mitochondrial Superoxide, Thereby Impairing CD8^+^ T Cell Effector Memory Formation during Contraction Phase {#S6}
----------------------------------------------------------------------------------------------------------------------------------------------------

Accumulation of mitochondria in immune cells has been shown to elevate mitochondrial superoxide ([@R22]; [@R76]). Hence, we stained Ova-specific CD8^+^ T cells with MitoSOX Red during the contraction phase and found significantly higher mitochondrial superoxide in T/NIX^−/−^ mice ([Figures 4A](#F4){ref-type="fig"}, [4B](#F4){ref-type="fig"}, [S5A](#SD1){ref-type="supplementary-material"}, and [S5B](#SD1){ref-type="supplementary-material"}). Because mitochondrial superoxide induces mitophagy of dysfunctional mitochondria so as to mitigate mitochondrial stress ([@R15]; [@R43]; [@R96]), we hypothesized that elevation of mitochondrial superoxide in absence of NIX-mediated mitophagy would exacerbate mitochondrial stress in antigen-specific CD8^+^ T cells. Indeed, we found that mitochondrial stress in T/NIX^−/−^ Ova-specific CD8^+^ T cells was significantly higher during the contraction phase, as indicated by increased mitochondrial membrane depolarization ([@R24]; [@R39]; [@R110]; [Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}) and mtDNA damage ([@R39]; [@R52]; [Figure S5C](#SD1){ref-type="supplementary-material"}). This suggests that deletion of NIX caused an elevation of superoxide in the accumulated mitochondria of virus-specific CD8^+^ T cells during contraction phase, and this likely increased mitochondrial stress during effector-to-memory transition.

We next asked whether this increase in mitochondrial superoxide during contraction phase was responsible for defective CD8^+^ T cell effector memory formation in the absence of NIX. Because we observed that both impairment in effector memory formation and accumulation of mitochondrial superoxide occurred during contraction phase (days 10--20 p.i.), we chose day 13 p.i. as the time point for injecting N-acetyl cysteine (NAC), a scavenger of mitochondrial superoxide ([@R22]; [@R76]), into WT and T/NIX^−/−^ mice. Administration of NAC restored effector memory formation in T/NIX^−/−^ Ova-CD8^+^ T cells both *in vivo* ([Figures 4E](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"}) and *in vitro* ([Figures 4G](#F4){ref-type="fig"} and [4H](#F4){ref-type="fig"}). Treatment of WT groups *in vivo* and *in vitro* with NAC did not significantly alter CD8^+^ T cell effector memory formation, suggesting that over-accumulation of mitochondrial superoxide during contraction phase in T/NIX^−/−^ mice contributed to impaired CD8^+^ T cell effector memory formation. Furthermore, treatment with NAC rescued defective proliferation of T/NIX^−/−^Ova-EM during memory recall response ([Figure S5D](#SD1){ref-type="supplementary-material"}).

Mitochondrial Superoxide Elevates HIF1α during Contraction Phase in T/NIX^−/−^ Mice {#S7}
-----------------------------------------------------------------------------------

Mitochondrial superoxide increases expression of hypoxia-inducible factor 1 (HIF1α) in mammalian cells ([@R18], [@R19]), which is required for metabolism in activated CD8^+^ T cells ([@R57]; [@R79]; [@R69]). We therefore performed intracellular staining for HIF1α protein in Ova-EM generated *in vivo* 30 days after VSV-Ova immunization and found significantly elevated HIF1α in T/NIX^−/−^ Ova-EM ([Figures 5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}, [S5E](#SD1){ref-type="supplementary-material"}, and [S5F](#SD1){ref-type="supplementary-material"}). Although WT Ova-CD8^+^ downregulated HIF1α protein during transition from peak primary response (day 6 p.i.) to contraction phase (day 13 p.i.), HIF1α protein continued to stay elevated in T/NIX^−/−^ Ova-CD8^+^ even during the contraction phase ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}), suggesting that mitochondrial superoxide likely upregulated HIF1α during effector-to-memory transition phase. Because HIF1α is upregulated in activated T cells ([@R68]) expressing KLRG1 ([@R85]; [@R100]), it was also possible that elevation of HIF1α in T/NIX^−/−^ antigen-specific CD8^+^ T cells was a result of altered KLRG1 differentiation during contraction phase. However, we found that the upregulation of HIF1α occurred regardless of KLRG1 differentiation during effector memory formation in T/NIX^−/−^ Ova-CD8^+^ T cells ([Figures S5G](#SD1){ref-type="supplementary-material"} and [S5H](#SD1){ref-type="supplementary-material"}). We next measured intracellular HIF1α protein level in Ova-EM isolated from T/NIX^−/−^ mice, which were treated with NAC during the contraction phase. Removal of mitochondrial superoxide by NAC treatment reversed HIF1α accumulation in T/NIX^−/−^ Ova-EM ([Figures 5E](#F5){ref-type="fig"} and [5F](#F5){ref-type="fig"}), supporting that HIF1α accumulation is a downstream effect of mitochondrial superoxide. These data suggest that increased mitochondrial superoxide during the contraction phase increased HIF1α level during CD8^+^ T cell effector memory formation in T/NIX^−/−^ mice.

Elevated HIF1α Alters Mitochondrial Fatty Acid Metabolism during CD8^+^ T Cell Effector Memory Formation in T/NIX^−/−^ Mice, Leading to Impairment in ATP Synthesis {#S8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

We next investigated the mechanism through which HIF1α acts during effector memory formation in antigen-specific CD8^+^ T cells. Chronic HIF1α expression in mammalian cells inhibits expression of fatty acid synthase (*Fasn*) ([@R84]). FASN participates in the synthesis of long-chain fatty acids, which memory CD8^+^ T cells depend upon for their metabolism ([@R75]; [@R99]). In T/NIX^−/−^ mice, we saw significantly decreased *Fasn* expression in Ova-EM ([Figure 6A](#F6){ref-type="fig"}), indicating that T/NIX^−/−^ Ova-CD8^+^ likely funnel their bioenergetic activities through an alternative metabolic pathway during effector memory formation. Hence, we performed PCR array for T cell metabolic pathways ([@R3]; [@R32]) and found significant upregulation in the expression of short/branched-chain specific acyl-CoA dehydrogenase (*Acadsb*) in T/NIX^−/−^ Ova-EM ([Figure 6B](#F6){ref-type="fig"}). ACADSB contributes to oxidation of short/branched-chain fatty acids ([@R2]; [@R45]; [@R63]; [@R105]); thus, T/NIX^−/−^ Ova-CD8^+^ T cells likely exhibited a shift in fatty acid metabolism during effector memory formation. Consistent with reduced long-chain fatty acid synthesis, we observed a decrease in gene expression of long-chain acyl-CoA dehydrogenase (*Acadl*) ([Figure 6B](#F6){ref-type="fig"}), as this enzyme carries out β-oxidation of long-chain fatty acids synthesized by FASN ([@R55]). Moreover, we noted no significant alteration in glycolysis, glutaminolysis, short/medium/very long chain fatty acid oxidation, or peroxisomal fatty acid oxidation ([Figure 6B](#F6){ref-type="fig"}). A shift to short/branched-chain fatty acid oxidation was further verified in T/NIX^−/−^ Ova-EM by decreased expression of branched-chain-α-keto acid dehydrogenase kinase (*Bckdk*) ([Figure 6C](#F6){ref-type="fig"}), an enzyme that restricts synthesis of short/branched-chain fatty acids from branched-chain amino acids (BCAAs) ([@R37]; [@R97]). Consistently, upregulated short/branched-chain fatty acid metabolism resulted in an increased synthesis of 2-methylbutyrate, isobutyrate and isovalerate, the short/branched-chain fatty acids regulated by BCKDK ([@R25]) during effector memory formation in T/NIX^−/−^ Ova-CD8^+^ T cells, as measured by liquid chromatography-mass spectrometry (LC-MS) ([Figures S6A](#SD1){ref-type="supplementary-material"} and [S6B](#SD1){ref-type="supplementary-material"}). These data suggest a shift from long-chain fatty acid oxidation to short/branched fatty acid oxidation during effector memory formation in T/NIX^−/−^ Ova-specific CD8^+^ T cells.

We next induced effector memory formation in Ova-specific CD8^+^ T cells *in vitro* in the presence of CAY10585, an inhibitor of HIF1α accumulation ([@R58]), and observed complete restoration of *Fasn* ([Figure 6D](#F6){ref-type="fig"}) and *Bckdk* ([Figure 6D](#F6){ref-type="fig"}) expression in T/NIX^−/−^ CD8^+^ T cells. Likewise, treatment with NAC during the contraction phase also restored expression of both *Fasn* ([Figure S6C](#SD1){ref-type="supplementary-material"}) and *Bckdk* ([Figure S6D](#SD1){ref-type="supplementary-material"}) during effector memory formation in T/NIX^−/−^ mice. We next measured mitochondrial respiration in Ova-EM by extracellular flux analysis, which quantifies oxygen consumption rate (OCR) in real time. Decreased OCR after addition of etomoxir, an inhibitor of long-chain fatty acid oxidation ([@R78]), represented the extent to which Ova-EM carried out long-chain fatty acid oxidation. Long-chain fatty acid metabolism was significantly impaired in T/NIX^−/−^ Ova-EM but was restored upon HIF1α inhibition by CAY10585 during effector memory formation ([Figure 6E](#F6){ref-type="fig"}). We also verified upregulation of short/branched-chain fatty acid metabolism during effector memory formation in T/NIX^−/−^ CD8^+^ T cells via extracellular flux analysis. We measured any change in OCR upon addition of BCAAs to Ova-EM that were cultured in BCAA-free media during the measurement. Consistent with reduced BCKDK ([Figure 6C](#F6){ref-type="fig"}) and increased ACADSB ([Figure 6B](#F6){ref-type="fig"}), OCR in T/NIX^−/−^ Ova-EM increased upon addition of BCAAs, which was reversed after treatment with CAY10585 ([Figure 6F](#F6){ref-type="fig"}). Additionally, we found that short/branched-chain fatty acid oxidation played a critical role in partially rescuing the formation of effector memory in T/NIX^−/−^ CD8^+^ T cells because knocking out ACADSB ([Figures S7A](#SD1){ref-type="supplementary-material"} and [S7B](#SD1){ref-type="supplementary-material"}) reduced effector memory formation even further ([Figure 6G](#F6){ref-type="fig"}). Interestingly, short/branched-chain fatty acid oxidation was found to be critical for effector memory formation in WT CD8^+^ T cells as well ([Figure 6G](#F6){ref-type="fig"}), suggesting that short/branched-chain fatty acid oxidation might be a critical metabolic pathway in addition to long-chain fatty acid oxidation during CD8^+^ T cell effector memory formation. These data indicate that elevated HIF1α "sHIFted'" the metabolism from long-chain fatty acid oxidation to short/branched-chain fatty acid oxidation during CD8^+^ T cell effector memory formation in T/NIX^−/−^ mice. Additionally, treatment of ACADSB^−/−^ CD8^+^ T cells with rapamycin modestly improved effector memory formation only in WT, but not T/NIX^−/−^ CD8^+^ T cells, and was unable to achieve a complete restoration ([Figure S7C](#SD1){ref-type="supplementary-material"}).

Because the length of metabolized fatty acids dictates the amount of ATP generated ([@R17]), increased dependence on short/branched fatty acid metabolism in T/NIX^−/−^ mice could potentially compromise ATP generation during CD8^+^ T cell effector memory formation. We observed a significant reduction in ATP synthesis in T/NIX^−/−^ Ova-EM compared with WT Ova-EM ([Figure 6H](#F6){ref-type="fig"}) that was restored upon removing mitochondrial superoxide during contraction phase in T/NIX^−/−^ mice ([Figure S7D](#SD1){ref-type="supplementary-material"}). Furthermore, ATP synthesis was restored in T/NIX^−/−^ Ova-specific CD8^+^ T cells during effector memory formation in the presence of CAY10585 ([Figure 6I](#F6){ref-type="fig"}). We also used LentiCRISPRv2-mediated CRISPR-Cas9 genome editing (sgRNA-HIF1α) to knockout HIF1α ([Figures S7E](#SD1){ref-type="supplementary-material"} and [S7F](#SD1){ref-type="supplementary-material"}) in CD8^+^ T cells during effector memory formation. Because deleting HIF1α early during the activation of CD8^+^ T cells prevented their survival ([Figure S7G](#SD1){ref-type="supplementary-material"}), we performed LentiCRISPRv2-mediated HIF1α deletion on day 3 post-activation in CD8^+^ T cells and achieved a selective transduction in post-activated CD8^+^ T cells (91.65% ± 2.17% for sgRNA-HIF1α and 72.45% ± 1.318% for sgRNA-HIF1α^2nd^) ([Figures S7H](#SD1){ref-type="supplementary-material"} and [S7I](#SD1){ref-type="supplementary-material"}). Upon ablation of HIF1α from post-activated T/NIX^−/−^ Ova-CD8^+^, ATP synthesis was restored during effector memory formation ([Figure 6J](#F6){ref-type="fig"}). These data suggest that elevated HIF1α during effector memory formation in T/NIX^−/−^ antigen-specific CD8^+^ T cells switched metabolism from long-chain fatty acid oxidation to short/branched-chain fatty acid oxidation, resulting in decreased ATP synthesis.

Inhibiting HIF1α Accumulation Restores Effector Memory Formation in Antigen-Specific T/NIX^−/−^ CD8^+^ T Cells {#S9}
--------------------------------------------------------------------------------------------------------------

Finally, we explored if restoring mitochondrial fatty acid metabolism and ATP synthesis by inhibiting HIF1α would also restore effector memory formation in T/NIX^−/−^ CD8^+^ T cells. We found that impaired effector memory formation in these cells was rescued upon treatment with CAY10585 ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}) and CRISPR-Cas9-mediated deletion of HIF1α ([Figures 7C](#F7){ref-type="fig"} and [S7J](#SD1){ref-type="supplementary-material"}).

We next investigated whether the impairment in effector memory formation in T/NIX^−/−^CD8^+^ T cells was a result of defective ATP synthesis. We induced CD8^+^ T cell effector memory formation *in vitro* in the presence of both CAY10585 and oligomycin, an inhibitor of mitochondrial ATP synthesis. Treatment with oligomycin abolished the restoration of effector memory formation in T/NIX^−/−^CD8^+^ T cells that was otherwise achieved by CAY10585 treatment ([Figure 7D](#F7){ref-type="fig"}), suggesting that the defective effector memory formation due to HIF1α accumulation in T/NIX^−/−^CD8^+^ T cells was ultimately caused by insufficient ATP generation. In addition, treatment with oligomycin impaired effector memory formation in WT CD8^+^ T cells to a level comparable with that in vehicle-treated T/NIX^−/−^CD8^+^ T cells ([Figure 7D](#F7){ref-type="fig"}), further supporting that inadequate mitochondrial ATP synthesis was the cause of impaired effector memory formation in T/NIX^−/−^CD8^+^ T cells. These data suggest that HIF1α-mediated suppression of ATP generation was responsible for the impaired effector memory formation in antigen-specific T/NIX^−/−^ CD8^+^ T cells.

We further observed that in VSV-Ova-infected mice that were pre-injected with WT or T/NIX^−/−^ Ova-EM, T/NIX^−/−^ Ova-EM-recipient mice had significantly reduced concentration of IFN-γ after infection ([Figure 7E](#F7){ref-type="fig"}). In contrast, CAY10585-treated T/NIX^−/−^ Ova-EM-recipient mice had restored IFN-γ production ([Figure 7E](#F7){ref-type="fig"}). IFN-γ plays a pivotal role in the protective immunity against intracellular viral infections ([@R56]). Consistently, mice that received vehicle-treated T/NIX^−/−^ Ova-EM had higher viral load, and this defect was rescued in mice that received CAY10585-treated T/NIX^−/−^ Ova-EM ([Figure 7F](#F7){ref-type="fig"}). These data highlight a pivotal role of HIF1α in impairing effector memory formation in T/NIX^−/−^ antigen-specific CD8^+^ T cells, leading to a compromised immunity against cytopathic viral infection.

DISCUSSION {#S10}
==========

We show that deficiency in NIX-dependent mitophagy leads to increased apoptosis in CD8^+^ MPECs and defective differentiation of effector memory CD8^+^ T cells. Moreover, impaired mitophagy resulted in the accumulation of mitochondrial superoxide and HIF1α in virus-specific CD8^+^ T cells during contraction phase. This promoted short/branched-chain fatty acid oxidation at the expense of long-chain fatty acid oxidation, thereby decreasing ATP synthesis, negatively affecting CD8^+^ T cell effector memory formation and compromising recall response against cytopathic viral infection.

Our study also demonstrates that TCR signaling during primary response downregulates NIX expression in virus-specific activated CD8^+^ T cells. Downregulation of NIX could allow accumulation of depolarized mitochondria, which is required to mediate optimal T cell activation ([@R6]) via mitochondrial superoxide ([@R29]). However, upon entering contraction phase, these antigen-specific CD8^+^ T cells upregulate their NIX expression to clear off superoxidegenerating depolarized mitochondria to form optimal effector memory against the virus. We further found that IL-15 signaling upregulated *Nix* expression *in vitro*. However, whether IL-15 signaling is required to upregulate NIX expression *in vivo* remains to be determined.

Loss of NIX led to mitochondrial accumulation in effector memory, but not naive or central memory, CD8^+^ T cells, suggesting that NIX-mediated mitophagy plays a selective role in CD8^+^ T cell effector memory formation. It is intriguing how NIX plays a tissue-specific role during T cell effector memory formation but not central memory formation. It could be related to chromatin remodeling unique to effector memory development. In fact, chromatin remodeling unique to the development of tissue-resident memory T cells has been reported to predispose RUNX3 to selectively favor differentiation of tissue-resident memory T cells over central or effector memory T cells ([@R70]). These unique chromatin landscapes favoring the formation of different subsets of memory T cells could in turn be regulated by unique DNA methylation patterns determining the fate of memory in virus-specific T cells ([@R1]; [@R113]). Alternatively, other molecules might play a more pivotal role in mediating mitophagy in central memory population. FUNDC1 and BCL2L13, which are also outer mitochondrial membrane proteins, have also been reported to mediate mitophagy in mammalian cells ([@R62]; [@R71]; [@R86]). Hence, it is possible that these molecules might regulate mitophagy during T cell central memory formation. These possibilities, however, need to be experimentally verified through future studies.

Impaired mitophagy during effector memory formation in T/NIX^−/−^ CD8^+^ T cells further led to excessive mitochondrial superoxide during contraction phase. Although mitochondrial superoxide is necessary for CD8^+^ T cell primary response ([@R51]; [@R73]), our data suggest that its continued presence during contraction phase blocks effector memory formation. Mitochondrial superoxide caused HIF1α accumulation during the contraction phase of effector memory formation in T/NIX^−/−^ mice. Scavenging mitochondrial superoxide significantly reduced HIF1α protein accumulation. We also found that blocking HIF1α expression early during T cell activation reduced frequency of activated CD8^+^ T cells, suggesting that HIF1α is necessary for activation of these cells, likely because of its role in upregulating glycolysis ([@R57]; [@R79]; [@R69]; [@R101]). However, continued presence of HIF1α during contraction phase was detrimental to CD8^+^ T cell effector memory formation in T/NIX^−/−^ mice.

We also found that accumulation of HIF1α during effector-to-memory transition in T/NIX^−/−^ CD8^+^ T cells "sHIFted" their metabolism to short/branched-chain fatty acid oxidation, which was unexpected because this pathway is less efficient in generating ATP compared with alternative pathways, especially very long chain fatty acid oxidation, which did not alter in the absence of NIX. One explanation for choosing short/branched-chain fatty acids over very long chain fatty acids by T/NIX^−/−^ CD8^+^ T cells might be that the former can readily diffuse into the mitochondrial matrix ([@R28]) as opposed to very long chain fatty acids, which require ATP-dependent active transporters ([@R44]; [@R108]). Hence, catabolizing short/branched-chain fatty acids was probably bioenergetically more favorable during effector memory formation in T/NIX^−/−^ CD8^+^ T cells, which were already deficient in ATP during contraction phase. Short-chain fatty acids did not play a significant role during effector memory formation either, possibly because of mammalian cells' inability to synthesize short-chain fatty acids *de novo*, which they obtain from gut bacteria ([@R28]); thus, absence of NIX in CD8^+^ T cells would not likely alter the supply of short-chain fatty acids. Medium-chain fatty acids would be expected to be less efficient than short/branched-chain fatty acids in diffusing into mitochondria, because of sterically bulkier carbon chain. All these reasons probably left short/branched-chain fatty acid oxidation as the best alternative during effector memory formation in T/NIX^−/−^ CD8^+^ T cells. It is also interesting that short/branched-chain fatty acid oxidation played a critical role at an early stage during CD8^+^ T cell effector memory formation, and deletion of NIX likely promoted this pathway to compensate for the impaired long-chain fatty acid metabolism during effector memory formation. Because enhancing long-chain fatty acid oxidation has been shown to improve T cell memory formation ([@R101]), it is possible that overexpression of FASN in ACADSB^−/−^ CD8^+^ T cells could improve effector memory formation as well. However, this needs to be further tested.

NK cells are dependent on BNIP3 but only partially reliant on NIX for their survival through the contraction phase ([@R76]). Interestingly, we found that NIX is required for optimal generation of CD8^+^ effector memory, whereas BNIP3 is dispensable. This suggests that NIX and BNIP3, two homologous proteins, may play tissue-specific roles in different cell types. We further found that PINK1 and PARK2, another set of mitophagy molecules, were not significantly upregulated during memory formation. Consistently, reduced frequency of CD8^+^ T cells was not detected on day 13 p.i. in PINK1^−/−^ mice either ([@R65]). In addition, deletion of *Pink1* did not alter mitochondrial stress and long-chain fatty acid metabolism in T cells ([@R31]). Together, these data suggest a non-critical role of PINK1 during CD8^+^ T cell memory formation. PARK2, which is activated by PINK1 ([@R35]), wastemporally downregulated during memory formation, consistent with no reduction in T cell frequency in absence of PARK2 during viral infection, as reported elsewhere ([@R60]). Although the exact mechanism of *Park2* downregulation during T cell memory formation needs to be further elucidated, one possible mechanism could be related to midnolin (*Midn*) expression, which mediates gene expression of *Park2* ([@R74]) and has also been reported to be expressed in T cells ([@R38]). However, whether *Park2* downregulation during T cell memory formation is regulated by midnolin is a subject for future studies. Taken together, these data suggest that despite their roles in regulating mitophagy, PINK1 and PARK2 likely do not play a critical role as NIX does in T cell memory formation.

To date, the development of successful vaccines against several viral pathogens has been challenged by the inability of vaccines to elicit a robust CD8^+^ T cell effector memory formation ([@R103]; [@R91]). Efficacy of experimental cancer vaccines has also been found to depend on the strength of immunological memory formation in tumor-specific T cells ([@R8]; [@R42]). In addition, T cell effector memory formation against auto-antigens has been shown to exacerbate the symptoms associated with auto-immune disorders, and inhibition of auto-antigen-specific effector memory T cells could alleviate those symptoms ([@R12]; [@R9]; [@R10]; [@R20]; [@R66]). Our findings have implications for advancing the fields of vaccine, cancer immunotherapy, and auto-immunity research by targeting NIX, HIF1α, and metabolism of long-chain as well as short/branched-chain fatty acids.
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### Animals {#S14}

All mice used in the study were bred at Baylor College of Medicine in agreement with the guidelines of the Institutional Animal Care and Use Committee. For the generation of T/NIX^−/−^ mice, B6.Cg-Tg(Lck-cre)548Jxm/J mice (LCK^Cre^ mice; The Jackson Laboratory) were cross-bred with NIX^f/f^ mice ([@R30]). In T/NIX^−/−^ mice, NIX was flanked with LoxP sequences and expression of Cre was regulated under Lymphocyte protein tyrosine kinase (Lck) promoter. Other strains of mice used in the study were: C57BL/6J (WT or CD45.2^+^ mice), B6.SJL-Ptprc^a^ Pep3^b^/BoyJ (CD45.1^+^ mice) and C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I mice) mice, all of which were purchased from The Jackson Laboratory. OT-I T/NIX^−/−^ mice were generated by cross-breeding OT-I and T/NIX^−/−^ mice, and OT-I Lck^Cre^ mice were generated by cross-breeding OT-I and Lck^Cre^ mice. Experiments were conducted with age-matched (mice aged 6 to 16 week old were used) and gender-matched (both male and female mice were used) mice. In all experiments, WT or OT-I or OT-I Lck^Cre^ mice were used as controls.

### Cell lines and primary cell cultures {#S15}

Splenocytes harvested from the mice were cultured in T cell media \[RPMI 1640 (Corning)+10% FBS (GIBCO)+1X antibiotic-antimycotic (GIBCO)\]. BHK-21, 293T and 3T3 cells were maintained in DMEM/High-glucose (HyClone)+10% FBS (GIBCO)+1X antibiotic-antimycotic (GIBCO).

METHOD DETAILS {#S16}
--------------

### Virus, immunization and infection {#S17}

Vesicular Stomatitis Virus co-expressing Ovalbumin (VSV-Ova) was propagated in BHK-21 cells at an MOI of 0.01, and concentrated at 15,000 rpm in an SW28 (Beckman) rotor for 5 hours. Viral titer was determined using plaque assay on BHK-21 cells. Gender- and age-matched mice were immunized with 10^4^ PFU of VSV-Ova via tail vein injection. For infection experiments, mice were injected with 10^6^ PFU of VSV-Ova via tail-vein injection. In all injections, VSV-Ova was suspended in sterile 1X DPBS (GIBCO).

### Flow cytometry {#S18}

Ova-specific effector memory CD8+ T cells and Ova-specific activated CD8+ T cells were pre-treated with FcRγII/III (Fc blocker) and IgG~2b~ anti-mouse CD16/CD32 antibodies, then stained with the following anti-mouse fluorescent-conjugated antibodies: CD3 (Biolegend\#100236), CD8 (Biolegend \#100712/\#100725), CD44 (Biolegend\#103006/\#103012/\#103062), CD62L (Biolegend\#104418), CD43 (Biolegend \#121224), CD127 (Thermo Fisher Scientific\#15-1271-81/Biolegend\#135010), KLRG1 (Biolegend\#138416), CD45.2 (BD PharMingen\#553772), CXCR5 (Biolegend\#145513), TIM3 (Biolegend\#134009), TCF7 (R&D Systems \# FAB8224R) and SIINFEKL peptide-specific Ova_tetramer (Baylor College of Medicine's MHC tetramer production facility \#16114) and finally analyzed on BD FACSCantoII (BD Biosciences) or BD LSRII (BD Biosciences). For MitoTracker Green staining, Ova-specific effector memory CD8+ T cells were stained with 100nM MitoTracker Green FM (Invitrogen) and analyzed on BD FACSCantoII. For MitoSOX Red staining, Ova-specific CD8+ T cells were stained with 5uM MitoSOX Red (Molecular Probes) and analyzed on BD FACSCantoII. For CytoID staining, Ova-specific effector memory CD8+ T cells or naive CD8+ T cells were pre-treated with 10uM chloroquine for 2 hours to inhibit autophagosomal degradation, followed by detection of autophagy flux using Cyto-ID autophagy detection kit (Enzo) according to manufacturer's instructions. For experiments involving CFSE staining, cells were labeled with 5uM of CFSE prior to stimulation with 1ug/mL anti-mouse CD3 (BD Biosciences\#553058) and 1ug/mL anti-mouse CD28 (BD Biosciences\#553294) antibodies or stained with 5uM of CFSE prior to the adoptive transfer. Cells not stained with CFSE served as unstained control; and CFSE stained cells which were either not stimulated with CD3/CD28- amtibodies or not adoptively transferred into the recipients served as non-activated control. All analyses were done using FlowJo software.

### CD8^+^ population enrichment and cell sorting {#S19}

For enrichment with CD8^+^ population, cells were labeled with CD8a microbeads (Miltenyi) and magnetically sorted using autoMACS (Miltenyi). CD8^+^ population was then pre-treated with FcRγII/III (Fc blocker) and IgG~2b~ anti-mouse CD16/CD32 antibodies, and stained with fluorescent-conjugated antibodies against mouse- CD8 (Biolegend\#100712/\#100725/\#100766), CD44 (Biolegend \#103006/Biolegend \#103012/Biolegend \#103062), CD62L (Biolegend \# 104418/\#104450), CD43 (Biolegend\#121224), CD127 (Thermo Fisher\#15-1271-81/Biolegend \#135010), KLRG1 (Biolegend\#138416), CXCR5 (Biolegend\#145513), TIM3 (Biolegend\#134009), TCF7 (R&D Systems\#FAB8224R) and Ova_tetramer (Baylor College of Medicine's MHC tetramer production facility\#16114 or \#19020) for Ova-EM, Ova-CM, naive CD8^+^ and Ova- CD8^+^ MPEC. In addition, Ghost Dye Violet 510 (Tonbo \#13--0870) or NucBlue DAPI (Invitrogen \#R37606) were also used to selectively sort live cells. In those cases, Ghost Dye Violet 510^−^ or NucBlue DAPI^−^ populations were further sub-gated into Ova-EM, Ova-CM, naive CD8^+^ and Ova-CD8^+^ MPEC. Stained cells were sorted on BD FACSAriaII (BD Biosciences). Typical purity after cell sorting was \> 95%.

### Effector memory formation in CD8^+^ T cells *in vitro* {#S20}

Splenocytes were pulsed with Ovalbumin and cultured in T cell media, 55uM of 2-Mercaptoethanol (GIBCO) and 100units/mL IL-2 for 3 days, after which the cells were washed with 1X PBS (containing 2% adult serum) and cultured in T cell media and 20ng/mL mouse IL-15 (Biosource/Biolegend) for five additional days. For effector memory formation in case of extracellular flux analysis and CRISPR/Cas9-mediated gene knockout experiments, splenocytes from OT-I (OT-I WT) or OT-I x LCK^Cre^ (OT-I WT) or OT-I x NIX^f/f^ (OT-I WT) and OT-I x LCK^Cre^ x NIX^f/f^ (OT-I T/NIX^−/−^) mice were used.

For experiments where gene expression of NIX was measured, CD8^+^ T cells from naive OT-I mice were stimulated with either 1ug/mL each of anti-CD3 or anti-CD3/CD28 antibodies for 3 days. CD8^+^ T cells were then washed and 20ng/mL of fresh IL-15 was added.

### Adoptive transfer {#S21}

For memory recall experiments (flow cytometry and ELISA for IFN-γ and IL-2), equal number of sorted Ova-specific effector memory CD8^+^ T cells (CD45.2^+^), that were formed either *in vivo* or *in vitro*, were resuspended in sterile 1X DPBS and injected into naive CD45.1^+^ mice via tail vein injection. In case of experiments, where protection against VSV-Ova infection was assessed (viral titer and ELISA for IFN-γ), equal number of cells on day 8 of *in vitro* formation of effector memory were injected into naive CD45.1^+^ mice via tail vein injection. Recipient naive CD45.1^+^ mice were challenged with 10^4^ PFU (memory recall experiments) or 10^6^ PFU (infection experiments) of VSV-Ova via tail vein injection 24 hours later. 48 hours after VSV-Ova challenge/infection, mice were sacrificed and their peripheral organs or blood were harvested for further analysis. For CFSE proliferation assay, Ova-specific effector memory CD8^+^ T cells were labeled with 5uM CFSE before adoptive transfer.

### Quantitative PCR and PCR array of metabolic genes {#S22}

To assess the expression of genes, Ova-specific effector memory CD8^+^ T cells (Ova-EM) or Ova-specific central memory CD8^+^ T cells (Ova-CM) or Ova-specific memory precursor effector cells (Ova-CD8^+^ MPECs) or Ova-specific reactivated Ova-EM were sorted and total RNA was extracted using Direct-zol RNA microprep kit (Zymo Research). Extracted RNA was then reverse-transcribed into cDNA using SuperScript IV VILO Master Mix with ezDNase Enzyme kit (Invitrogen). Quantitative PCR was performed using iTaq Universal Probes Supermix (Bio-Rad) with primers targeting mouse *18S* (Forward: 5′-ATTGACGGAAGGGCACCAC-3′; Reverse: 5′-TCTAAGAAGTTGGGGGACGC-3′), *Nix* (Forward: 5′- GAGCCGGATACTGTCGTCCT −3′; Reverse: 5′- CAATATAGATG CCGAGCCCCA −3′), *Bnip3* (Forward: 5′- AACAGCACTCTGTCTGAGGAA −3′; Reverse: 5′- TGTCAGACGCCTTCCAATGT −3′), *IL-15Rα* (Forward: 5′- ACATCGGTCCTCTTGGTTGG −3′; Reverse: 5′- CGTGTGGTTAGGCTCCTGTG −3′), *Foxo1* (Forward: 5′-CAC ACATCTGCCATGAACCG-3′; Reverse: 5′-GGTGGAGGACACCCATCCTA-3′), *Tcf7* (Forward: 5′-CGGAAAGAAGAAGAGGCGGT-3′; Reverse: 5′-CTGTCATCGGAAGGAACGGG-3′), *Blimp-1* (Forward: 5′- GGACTGGGTGGACATGAGAG −3′; Reverse: 5′- TTCACGTA GCGCATCCAGTT −3′), *Tfam* (Forward: 5′-TAGGCACCGTATTGCGTGAG −3′; Reverse: 5′- GACAAGACTGATAGACGAGGGG-3′), *Fasn* (Forward: 5′-TTGACGGCTCACACACCTAC-3′; Reverse: 5′-TTGTGGTAGAAGGACACGGC-3′), *Bckdk* (Forward: 5′-TTCCCCTT CATTCCCATGCC-3′; Reverse: 5′-CCGTAGGTAGACATCCGTGC-3′), *Pink1* (Forward: 5′- GTGGGACTCAGATGGCTGTC-3′; Reverse: 5′- GCACATTTGCAGCTAAGCGT-3′), *Parkin* (Forward: 5′- CCAAACCGGATGAGTGGTGAGTGC-3′; Reverse: 5′- ACACGG CAGGGAGTAGCCAAGTTG-3′) and *Caspase-3* (Forward: 5′- AGCTGGACTGTGGCATTGAG-3′; Reverse: 5′- CCACGACCCGTCC TTTGAAT-3′).

For PCR array of metabolic genes, primers targeting mouse *Acadl* (Forward: 5′- GTGTATCGGTGCCATAGCCA-3′; Reverse: 5′-AGGCAGAAATCGCCAACTCA-3′), *Acadsb* (Forward: 5'-3′; Reverse: 5′−3′), *Acadm* (Forward: 5′-TTCGAAGACGTCAGA GTGCC-3′; Reverse: 5′-GCTCCACTAGCAGCTTTCCA-3′), *Acads* (Forward: 5′-TTGCCGAGAAGGAGTTGGTC-3′; Reverse: 5′-AGG TAATCCAAGCCTGCACC-3′), *Acad11* (Forward: 5′-CGCCTTGGACCTGGAAGAAT-3′; Reverse: 5′-TTCAAGGTCAGCAAGCGG AT-3′), *Atp5b* (Forward: 5′-GTTGGTCCTGAGACCTTGGG-3′; Reverse: 5′-TCCGATTTTCCCACCCTTGG-3′), *Atp5f1* (Forward: 5′-TCCAGGGGTATTACAGGCAAC-3′; Reverse: 5′-CAGCCCAAGACGCACTTTTC-3′), *Ehhadh* (Forward: 5′-CGGTCAATGCCAT CAGTCCA-3′; Reverse: 5′-AGCACCTGCACAGAAGTTGT-3′), *Gls* (Forward: 5′-CCGCGGGCGACAATAAAATAA-3′; Reverse: 5′-GCATGACACCATCTGACGTT-3′), *Glut1* (Forward: 5′-ATAGTTACAGCGCGTCCGTT-3′; Reverse: 5′-AGAGACCAAAGCGTG GTGAG-3′), *Prkaa1* (Forward: 5′-GTGAAGATCGGCCACTACATCC-3′; Reverse: 5′-GGCTTTCCTTTTCGTCCAACC-3′), *Pdha1* (Forward: 5′-GCCACCCTGAACCTGAGAAA-3′; Reverse: 5′-GCGATACATCATTACATCCACG-3′) were used Quality control on all the primers was performed in-house to ensure band specificity, accuracy and reliability. Data were normalized to that for *18S* and expressed as relative abundance via 2^−ΔΔCT^ method, where CT is the threshold cycle. Unless specified in the figure legends, final results were represented relative to Day 0 time point (in case of NIX expression) or WT or WT (+DMSO) (in case of expression all other genes), as indicated in respective figures.

### Measurement of apoptosis in Ova-CD8^+^ MPECs and Ova-EM {#S23}

Splenocytes were harvested from WT and T/NIX^−/−^ mice 20 days after immunization with 10^4^ PFU of VSV-Ova, pre-treated with FcRγII/III (Fc blocker) and IgG~2b~ anti-mouse CD16/CD32 antibodies, and stained with the following anti-mouse fluorescent-conjugated antibodies: CD8 (Biolegend\#100725), CD44 (Biolegend\#103062), CD62L (Biolegend\#104418), CD43 (Biolegend\#121224), CD127 (Biolegend\#135010) and SIINFEKL peptide-specific Ova_tetramer (Baylor College of Medicine's MHC tetramer production facility\#16114). Next, surface stained splenocytes were washed with 1X PBS, incubated in Annexin V (BD PharMingen \#51--65874X) at room temperature (away from light) for 20 mins and analyzed on BD FACSCantoII within 1 hour. Percentage of Annexin V^+^ population in Ova-CD8^+^ MPECs and Ova-EM represented cells undergoing apoptosis.

### Immunocytochemistry {#S24}

Ova-specific effector memory CD8^+^ T cells, Ova-specific central memory CD8^+^ T cells or naive CD8^+^ T cells formed *in vivo* in WT and T/NIX^−/−^ mice were sorted 30 days after VSV-Ova immunization, treated with 10uM chloroquine for 2 hours to inhibit autophagosomal degradation, and applied to slides by cytospin. The cells were then fixed, permeabilized and incubated with mouse anti-COX IV (Invitrogen\#459600) and rabbit anti-LC3 (Abgent\#AP1801a) to stain mitochondria and autophagosomes respectively. This was followed by staining with Alexa Fluor conjugated secondary antibodies (Molecular Probes) and examination of slides under 100X objective (U PlanS-Apo/1.4, oil immersion) of deconvolution microscope (GE Healthcare Deltavision LIVE High Resolution) using SoftWoRx acquisition software. The Pearson coefficiency of correlation for LC3 and COX IV co-localization was determined using SoftWoRx software (Applied Precision).

### Measurement of mitochondrial membrane depolarization {#S25}

Splenocytes were harvested from WT and T/NIX^−/−^ mice 20 days after immunization with 10^4^ PFU of VSV-Ova, pre-treated with FcRγII/III (Fc blocker) and IgG~2b~ anti-mouse CD16/CD32 antibodies, and stained with the following anti-mouse fluorescent-conjugated antibodies: CD8 (Biolegend\#100725) and SIINFEKL peptide-specific Ova_tetramer (Baylor College of Medicine's MHC tetramer production facility\#16114). Next, surface stained splenocytes were washed and incubated in 2.5ug/mL of JC-1 in 37C for 30 mins. Splenocytes were then washed and analyzed on BD LSRII (BD Biosciences). Mitochondrial membrane depolarization was indicated by geometric MFI of green fluorescence corresponding to JC-1 monomers in Ova-specific CD8^+^ T cells.

### Mitochondrial DNA damage assay {#S26}

Mitochondrial DNA damage was assessed using mouse DNA Damage Analysis Kit (Detroit R&D\#DD2M) according to manufacturer's instructions. Briefly, 100,000 sorted Ova-specific CD8^+^ T cells from day 20 p.i. mice were lysed in lysis buffer (5M sodium chloride, 1M tris, 0.5M EDTA, 10% SDS and 0.3mg/mL proteinase K) at 56C overnight, followed by heat inactivation of proteinase K at 95C for 10 mins. Cell lysates were then diluted 10X in nuclease-free water before using further. Samples (\~5ng/uL DNA) were subjected to PCR reaction, after which 10X diluted PCR reaction product was subjected to real-time PCR. Final concentrations of damaged mitochondrial DNA were calculated from the 8.2kb standard curve plotted using 8.2kb real-time standard supplied with the kit.

### Drug treatments {#S27}

In experiments where CD8^+^ effector memory was formed *in vivo*, NAC (1mg/mouse) was dissolved in sterile 1X DPBS and injected intraperitoneally (i.p.) once on days 13, 20 and 27 after immunization with VSV-Ova. In experiments, where CD8^+^ effector memory was formed *in vitro*, 100uM of NAC (dissolved in sterile 1X DPBS) (Sigma Aldrich\#A7250) or 3uM of CAY10585 (dissolved in DMSO) (Cayman Chemical\#*934593-90-5*) or 10nM Oligomycin (dissolved in DMSO) or 100nM rapamycin (dissolved in DMSO) was added once on day 4 of culture.

### Intracellular staining {#S28}

Surface stained Ova-specific effector memory CD8^+^ T cells were fixed and permeabilized with Cytofix/Cytoperm kit (BD Biosciences), followed by staining with rabbit anti-mouse HIF1α antibody (Novus Biologicals\#nb100-449) or mouse anti-mouse TFAM (Santa Cruz Biotechnology\#sc-166965) at 4°C for 1 hour. This was followed by staining with Alexa Fluor conjugated secondary antibodies (Molecular Probes) at 4°C for 1 hour. In case of intracellular staining of IL-2 and IFN-γ, splenocytes harvested from CD45.1^+^ mice were pre-treated with FcRγII/III (Fc blocker) and IgG~2b~ anti-mouse CD16/CD32 antibodies, then stained with anti-mouse CD8 (Biolegend\#100725), anti-mouse CD45.2 (BD PharMingen\#561096) and anti-mouse Ova_tetramer before intracellular staining. Surface stained splenocytes were then fixed and permeabilized with Cytofix/Cytoperm kit (BD Biosciences\#554714), followed by staining with anti-mouse IL-2 (BD PharMingen\#554428) or anti-mouse IFN-γ (Biolegend\# 505806). In case of intranuclear staining for TCF7, surface stained cells were fixed and permeabilized using Foxp3/Transcription factor staining buffer set (eBioscience\#00-5523-00), followed by staining with anti-mouse TCF7/TCF1 antibody (R&D systems\#FAB8224R). Stained cells were analyzed on BD FACSCantoII or BD LSRII.

### CRISPR/Cas9-mediated deletion of Hif1α and Acadsb genes {#S29}

For generation of single guide RNA specific to *Hif1α* and *Acadsb* genes (sgRNA-HIF1α, sgRNA-HIF1α^2nd^ and sgRNA-ACADSB), the 20-nucleotide target sequence was selected to precede 5′-NGG protospacer-adjacent motif (PAM) sequence using CRISPR/Cas9 design tool ([@R98]). Oligonucleotides were annealed and cloned into BsmBI-BsmBI sites in LentiCRISPRv2 plasmid (Addgene plasmid \#82416). Unmodified LentiCRISPRv2 plasmid served as sgRNA-control in the study. The sgRNA sequences used in this study were: sgRNA-HIF1α (forward: 5′-CACCGAGCCCTAGATGGCTTTGTGA-3′ and reverse:5′-AAACTCACAAAGCCATC TAGGGCTC-3′), sgRNA-HIF1α^2nd^ (forward: 5′- CACCGAAGCATCCTGTACTGTCCTG-3′ and reverse:5′- AAACCAGGACAGTACAG GATGCTTC-3′) and sgRNA-ACADSB (forward: 5′- CACCGATGGATGAGAACTCAAAAA-3′ and reverse: 5′- AAACTTTTTGAGTTCT CATCCATC-3′).

To generate lentiviral particles, 8×10^6^ 293T cells were plated on a 10 cm dish, followed by co-transfection with 3ug LentiCRISPR plasmid (sgRNA- HIF1α, sgRNA-HIF1α^2nd^, sgRNA-ACADSB or sgRNA-control), 1.33ug psPAX (Addgene plasmid \#12260) and 0.6ug pMD2.G (Addgene plasmid \#12259) by Lipofectamine 2000 transfection method (Invitrogen). The viral supernatant was collected after 48 and 72 hours, passed through 0.2um PES filter, pooled and frozen in −80C until further use.

In order to knockout *HIF1α* and *Acadsb* gene from CD8^+^ T cells, splenocytes from OT-I (OT-IWT) orOT-I × LCK^Cre^(OT-I WT) or OT-I × NIX^f/f^ (OT-I WT) and OT-I × LCK^Cre^ × NIX^f/f^ (OT-I T/NIX^−/−^) mice were cultured in 24-well or 48-well plate pre-coated with 1ug/mL of anti-mouse CD3 antibody (Biolegend \#100359) and anti-mouse CD28 antibody (BD Biosciences \#553294) for 3 days. On day 3, cells were washed and 500,000 cells/well were plated in a flat-bottom 48-well plate in presence of 1mL of viral supernatant: sgRNA-HIF1α, sgRNA-HIF1α^2nd^, sgRNA-ACADSB or sgRNA-control (unmodified LentiCRISPRv2 plasmid) and 10ug/ml polybrene (Sigma-Aldrich). The plated cells were then centrifuged at 1000 g for 90min in 32C, followed by incubation in 37C incubator for additional 2 hours. The viral supernatant was finally replaced by T cell media containing 20ng/mL IL-15 and cultured for 5 additional days for CD8^+^ T cell effector memory formation.

### Western blotting {#S30}

For western blot studies to validate deletion of *Hif1α* via CRISPR-Cas9, cells were treated with 100uM of cobalt chloride for 6 hours prior to preparation of cell lysate. Cell lysate was prepared by incubating the cells in cell lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and 1x protease inhibitor cocktail from Roche) for 60 mins on ice. Cell lysates were then heat denatured at 95°C for 6 minutes, quantified for total protein content by Bio-Rad Protein assay (Hercules, CA), electrophoretically resolved on SDS-PAGE, transferred onto PVDF membrane, and probed with primary antibodies (Novus Biologicals\#NB100-449 for HIF1α, Novus Biologicals\#NBP1-97833 for ACADSB and Santa Cruz Biotechnology\#sc-47778 for β-actin) and horseradish peroxidase-conjugated secondary antibodies (Southern Biotechnology/Amersham). The blots were finally developed using Supersignal West Dura Extended Duration substrate (Thermo Scientific).

### Viral titer assays {#S31}

1×10^6^ cells at the end of day 8 of *in vitro* CD8^+^ T cell effector memory formation were resuspended in sterile 1X DPBS and injected into naive C57BL/6 mice via tail vein injection. 24 hours later, recipient mice were infected with 10^6^ PFU of VSV-Ova via tail vein injection. 48 hours after infection, mice were sacrificed, and their brains were harvested. Brains were mashed in 1.5mL of T cell media, centrifuged at 12000 rpm for 3min in 4C and viral supernatant was collected and stored in −80C until further use. In case of viral titer determination in peripheral blood, blood was collected from heart of mice (immediately after euthanasia), allowed to clot at room temperature for 30 mins and centrifuged at 1000 g for 10 mins at 4°C. Supernatant (serum) was collected and stored in −80C until further use.

For plaque assay, 1.75 × 10^6^ BHK-21 cells/well (plated a night before in 24-well plate), were incubated with diluted brain supernatant or 100uL serum for 4 hours in 37C (with intermittent shaking in between). Following this incubation, supernatant was aspirated and 50uL of plaque assay media (DMEM+ 2% FBS+1X antibiotic/antimycotic) was added, followed by addition of 2 mL overlay media (0.4% agarose+DMEM+2% FBS+1X antibiotic/antimycotic). The plate was then incubated in room temperature for 10 mins to solidify the overlay media. Following this incubation, cells were incubated in 37C for 24 hours. At the end of 24-hour incubation, the overlay media was gently removed, and wells were gently washed with 1X PBS once. The monolayer of BHK-21 cells was fixed with 4% paraformaldehyde solution for 30 minutes in room temperature, followed by gentle washing with sterile water once. This was followed by staining the monolayer with 0.2% Crystal Violet solution at room temperature for 30 mins. The wells were then gently washed with sterile water and number of colorless plaques were counted against violet background to get the viral titer.

### Serum isolation and ELISA {#S32}

After sacrificing the mice, as much blood as possible was collected from the heart. Blood was allowed to clot for 30 mins at room temperature after which it was centrifuged at 1000 g for 10 mins at 4°C. Supernatant was collected and stored in −80°C until further use. ELISA for mouse IL-2 and IFN-γ was then performed using ELISA Max kit (Biolegend) according to manufacturer's instructions.

### Measurement of short/branched-chain fatty acids {#S33}

Short/branched-chain fatty acids were extracted ([@R82], [@R83]; [@R104]) by adding 100ul of acetonitrile: water (1:1). Cells were homogenized and supernatant was collected. To 40uL of supernatant, 20 ul of 200 mM 12C6-3NPH and 120 mM EDC.HCl were added and incubated for 30 min at 37° C. The resulting mixture was cooled and made up to 1.91 mL with 10% aqueous acetonitrile. 10 ul of the solution injected in to LC-MS. Mouse liver pool was used for quality control. ESI negative mode was used for the measurement. SRM was used and gradient Containing 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). Separation of metabolites was performed on acquityUPLC HSS T3 1.8 um (2.1 × 100mM). The binary pump flow rate was 0.35 ml/min with a gradient starting 15% Bat 0min, 50% at 10 min, 100% at 10.1min,15% at 13.1 min, reequilibration till the end of the gradient 17 min. 10 μL of sample was injected and analyzed using a 6490 triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA) coupled to a HPLC system (Agilent Technologies, Santa Clara, CA) via SRM. Source parameters were as follows: Gas temperature- 250°C; Gas flow- 14 l/min; Nebulizer - 20psi; Sheath gas temperature - 350°C; Sheath gas flow-12 l/ min; Capillary - 3000 V positive and 3000 V negative; Nozzle voltage- 1500 V positive and 1500 V negative. Approximately 8--11 data points were acquired per detected metabolite. The data points for each metabolite obtained were represented as fold change relative to WT.

### Extracellular flux analysis (Seahorse assay) {#S34}

Equal number of sorted Ova-specific effector memory CD8^+^ T cells were plated in microplate pre-coated with Cell Tak. Extracellular flux analysis was performed in Seahorse XFe96 Analyzer (Agilent). For OCR measurement related to measuring long-chain fatty acid oxidation, cells were plated in bicarbonate-free RPMI (Agilent) with 20mM glucose, 1X glutamax and 1X sodium pyruvate. Mitochondrial spare respiratory capacity (SRC) was calculated as the mean difference between OCR after FCCP injection and basal OCR (before Oligomycin injection). Long-chain fatty acid oxidation was calculated as the difference between mean OCR after injection of FCCP and mean OCR after injection of etomoxir (200uM final concentration). Long-chain fatty acid oxidation was plotted as fold-change in OCR relative to WT (+DMSO). Oligomycin, FCCP, Rotenone and Antimycin A were injected at final concentrations of 1uM, 2uM, 100nM and 1uM respectively.

For OCR measurement related to measuring short/branched-chain fatty acid oxidation, cells were plated in Krebs-Henseleit Buffer (KHB) with 20mM glucose, 1X glutamax and 1X sodium pyruvate. BCAA (final concentration of 1-1.5 mg/mL leucine, 1-1.5 mg/mL isoleucine and 0.4-0.6 mg/mL valine) was injected during the measurement of OCR. Short/branched-chain fatty acid oxidation was calculated as:

Mean OCR after injection of BCAA/ Mean OCR before injection of BCAA.

### ATP assay {#S35}

Sorted Ova-specific effector memory CD8^+^ T cells were lysed in lysis buffer (150mM sodium chloride, 1mM EDTA, 50mM HEPES adjusted to pH 7.4, 10% glycerol and 1% NP40) for 1 hour on ice. The cell lysate was then centrifuged at 16000xg for 10 minutes, and supernatant collected and used for ATP assay. ATP assay was performed using ATP Determination kit (Invitrogen\#A22066) according to manufacturer's instructions. Results were represented as values relative to WT or WT (+DMSO), as applicable to relevant figures.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S36}
---------------------------------------

Data were presented as mean ± SEM and p values were calculated using two-tailed Student's t test, one-way or two-way ANOVA with Bonferroni's posttests as indicated in the figure legends. Statistical analyses were done using GraphPad Prism software, assuming normal data distribution and equal sample variance. For measurement of fatty acids, the data was log2-transformed and normalized with internal standard per-sample. Number of mice used in each group in the study was consistent with previously published studies of similar nature. Any statistical difference \< 0.05 was considered as significant and is indicated in figure legends.

DATA AND CODE AVAILABILITY {#S37}
--------------------------

This study did not generate any unique datasets or code.
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![NIX Is Critical for Formation of Effector Memory in Ova-Specific CD8^+^ T Cells\
Spleens from OT-I mice (A--D) or wild-type (WT) and T/NIX^−/−^ mice (E--K) were collected at designated time points.\
(A) Kinetics of *Nix* expression in Ova-specific CD8^+^ T cells (Ova-CD8^+^) after VSV-Ova immunization.\
(B) Gene expression of *Nix* in Ova-CD8^+^ 24 h after addition of IL-15. CD8^+^ T cells from naive OT-I mice were activated with anti-CD3 and anti-CD28 for 72 h, followed by IL-15 addition.\
(C) Kinetics of *Nix* expression in Ova-CD8^+^ after CD3-stimulation, followed by IL-15 addition.\
(D) Kinetics of *Il15ra* expression in Ova-CD8^+^ after VSV-Ova immunization. Ova-CD8^+^ from mice within the same experimental group in (A)--(D) were pooled before analysis.\
(E) Representative dot plot showing percentage of Ova-EM in WT or T/NIX^−/−^ spleens on day 30 p.i. with 10^4^ plaque-forming units (PFU) of VSV-Ova.\
(F) Mean frequencies of Ova-EM from (E).\
(G) Experimental model for adoptive transfer experiment performed in (H).\
(H) Left: representative plot showing percentages of CD45.1^+^ WT and CD45.2^+^ T/NIX^−/−^ Ova-EM in CD45.2^+^ T/NIX^−/−^ mice 30 days after VSV-Ova immunization. Right: mean frequencies of CD45.1^+^ WT and CD45.2^+^ T/NIX^−/−^ Ova-EM from experiment performed in the left panel.\
(I) Kinetics of effector memory formation in Ova-CD8^+^ *in vivo* in WT or T/NIX^−/−^ mice after VSV-Ova immunization.\
(J) Gene expression of *Nix* in day 0 naive, day 6 Ova-activated, day 10 Ova-CD8^+^ MPECs, day 30 Ova-EM, and day 30 Ova-CM in WT mice after VSV-Ova immunization.\
(K and L) Gene expression of *Foxo1* (left panel) and *Tcf7* (right panel) in day 10 Ova-CD8^+^ MPECs (K) or day 30 Ova-EM (L) harvested from WT or T/NIX^−/−^ spleens after VSV-Ova immunization.\
(M) *In vitro* differentiation of Ova-EM. Left: representative plot for percentage of WT or T/NIX^−/−^ Ova-EM on day 8. Right: mean frequency of Ova-EM from left panel.\
In (E) and (M), CD8^+^Ova_tetramer^+^ population (Ova-EM) was gated on CD3^+^CD8^+^CD43^−^CD62L^−^CD44^+^ population. Data are representative of two or more independent experiments (n = 3--10). Data were analyzed using one-way ANOVA with Bonferroni's posttest (mean ± SEM) in (A)--(D); two-tailed Student's t test (mean ± SEM) in (F), (H, right), (J)--(L), and (M, right); and two-way ANOVA with Bonferroni's posttests (mean ± SEM) in (I). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001. See also [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0002){#F1}

![Deletion of NIX Leads to an Impaired Memory Recall in Ova-Specific Effector Memory CD8^+^ T Cells\
Ova-EM formed *in vivo* (A--E) or *in vitro* (F--I) from CD45.2^+^ WT or T/NIX^−/−^ mice were adoptively transferred into naive CD45.1^+^ mice. CD45.1^+^ hosts were challenged with 10^4^ PFU of VSV-Ova 24 h later. Forty-eight hours later, spleen and serum were harvested for analyses.\
(A) CD45.2^+^ Ova-CD8^+^ in CD45.1^+^ recipients receiving *in vivo* generated CD45.2^+^ WT or T/NIX^−/−^ Ova-EM.\
(B) Serum IFN-γ (left) and IL-2 (right) in CD45.1^+^ recipients from (A).\
(C) Plot showing IFN-γ and IL-2 producing CD45.2^+^ Ova-CD8^+^ in CD45.1^+^ recipients receiving *in vivo* generated CD45.2^+^ WT or T/NIX^−/−^ Ova-EM.\
(D) Intracellular IFN-γ and IL-2 in CD45.2^+^ Ova-CD8^+^ in CD45.1^+^ recipients receiving CD45.2^+^ WT or T/NIX^−/−^ Ova-EM. Geometric mean fluorescence index (MFI) values for IFN-γ were 2,292 ± 130.1 (WT) and 1,831 ± 143.6 (T/NIX^−/−^). Geometric MFIs for IL-2 were 1,126 ± 88.91 (WT) and 920.7 ± 166.3 (T/NIX^−/−^).\
(E) *In vivo* proliferation of re-activated WT or T/NIX^−/−^ Ova-EM measured by CFSE staining. Peaks corresponding to G1, G2, G3, G4, and G5 represent the generations of cells after successive cell division cycles. Proliferation index: 1.611 ± 0.023 (WT) and 1.454 ± 0.026 (T/NIX^−/−^) (p \< 0.001).\
(F) CD45.2^+^ Ova-CD8^+^ in CD45.1^+^ recipients receiving *in vitro* generated CD45.2^+^ WT or T/NIX^−/−^ Ova-EM.\
(G) Serum IFN-γ and IL-2 in CD45.1^+^ recipients from (F).\
(H) Plot showing frequencies of IFN-γ- and IL-2-producing CD45.2^+^ Ova-CD8^+^ in CD45.1^+^ recipients receiving *in vitro* generated CD45.2^+^ WT or T/NIX^−/−^ Ova-EM.\
(I) Intracellular IFN-γ and IL-2 in CD45.2^+^ Ova-CD8^+^ in CD45.1^+^ recipients receiving *in vitro* generated CD45.2^+^ WT or T/NIX^−/−^ Ova-EM. Geometric MFIs for IFN-γ were 7,120 ± 503.1 (WT) and 5,363 ± 551.3 (T/NIX^−/−^). Geometric MFIs for IL-2 were 5,154 ± 394.6 (WT) and 2,668 ± 489.4 (T/NIX^−/−^).\
Data in (A), (B), and (E)--(G) are representative of two or more independent experiments (n = 3--9), and data in (C), (D), (H), and (I) are representative of three or four biological replicates per group. Data were analyzed using two-tailed Student's t test (mean ± SEM). \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0003){#F2}

![Deletion of NIX Leads to Mitochondrial Accumulation in Ova-Specific Effector Memory CD8^+^ T Cells\
Spleens from WT or T/NIX^−/−^ mice were collected 30 days p.i. with VSV-Ova for analyses.\
(A) Top: MitoTracker Green staining in Ova-EM. Bottom: geometric mean fluorescence index (MFI) of MitoTracker Green staining from top panel.\
(B) Representative image of WT or T/NIX^−/−^ Ova-EM stained with COX IV (mitochondria) and LC3 (autophagosomes) obtained by immunocytochemistry.\
(C and D) Mitochondrial median fluorescence index (MFI) (C) and (D) co-localization analysis of mitochondria and autophagosomes in Ova-EM from (B). For each independent experiment in (B)--(D), Ova-EM were pooled from mice within the same experimental group, and 150 cells/group were imaged. Each point represents one Ova-EM.\
(E) Gene expression of *Tfam* in Ova-EM. Ova-EM from mice within the same experimental group were pooled before analysis.\
(F) Intracellular staining of TFAM in Ova-EM.\
Data are representative of two or more independent experiments (n = 5--7). Data were analyzed using two-tailed Student's t test (mean ± SEM). \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001. ns, non-significant. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0004){#F3}

![Deletion of NIX Results in Elevation of Mitochondrial Superoxide, Thereby Impairing CD8^+^ T Cell Effector Memory Formation during Contraction Phase\
Spleens from WT and T/NIX^−/−^ mice were harvested on designated time points after immunization with 10^4^ PFU VSV-Ova.\
(A) MitoSOX Red staining in Ova-CD8^+^ from WT and T/NIX^−/−^ mice 20 days p.i.\
(B) Geometric MFI for mitochondrial superoxide in Ova-CD8^+^ from (A).\
(C) Mitochondrial membrane depolarization (JC-1 monomer fluorescence) in Ova-CD8^+^ from WT and T/NIX^−/−^ mice 20 days p.i.\
(D) Geometric MFI for JC-1 fluorescence in Ova-CD8^+^ from (C).\
(E) Representative plot showing percentage of Ova-EM 30 days p.i. in WT and T/NIX^−/−^ mice that were treated with NAC or vehicle control (PBS) on days 13, 20, and 27 p.i.\
(F) Mean frequencies of Ova-EM from (E).\
(G) Representative plot showing percentage of WT and T/NIX^−/−^ Ova-EM formed *in vitro*, after NAC or PBS treatment.\
(H) Mean frequencies of Ova-EM from (G).\
Data are representative of two or more independent experiments (n = 6--10). Data were analyzed using two-tailed Student's t test (mean ± SEM). \*p \< 0.05, \*\*p \< 0.01, and \*\*\*\*p \< 0.0001. ns, non-significant. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0005){#F4}

![Mitochondrial Superoxide Elevates HIF1α during Contraction Phase in T/NIX^−/−^ Mice\
Spleens from WT or T/NIX^−/−^ mice were collected at designated time points after immunization with 10^4^ PFU VSV-Ova.\
(A) Intracellular HIF1α protein level in Ova-EM 30 days p.i. in WT and T/NIX^−/−^ mice.\
(B) Geometric MFI of HIF1α protein staining from (A).\
(C) Intracellular HIF1α protein level in Ova-specific effector CD8^+^ T cells during peak primary response (day 6 p.i.) and contraction phase (day 13 p.i.) in WT and T/NIX^−/−^ mice.\
(D) Geometric MFI of HIF1α protein staining from (C).\
(E) Intracellular HIF1α protein level in Ova-CD8^+^ in NAC or PBS treated WT and T/NIX^−/−^ mice.\
(F) Geometric MFI of HIF1α protein staining from (E).\
Data are representative of two or more independent experiments (n = 3--12). Data were analyzed using two-tailed Student's t test (mean ± SEM) in (B) and (F) and two-way ANOVA with Bonferroni's posttest (mean ± SEM) in (D). \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001. ns, non-significant. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0006){#F5}

![Elevated HIF1α Alters Mitochondrial Fatty Acid Metabolism during CD8^+^ T Cell Effector Memory Formation in T/NIX^−/−^ Mice, Leading to Impairment in ATP Synthesis\
(A) Gene expression of *Fasn* in Ova-EM 30 days after immunization with 10^4^ VSV-Ova.\
(B and C) Gene expression of T cell metabolic genes (B) and *Bckdk* (C) in Ova-EM 30 days after VSV-Ova immunization in WT and T/NIX^−/−^ mice.\
(D) Gene expression of *Fasn* (left panel) and *Bckdk* (right panel) in Ova-EM formed *in vitro* (vehicle or CAY10585 treatment on day 4).\
(E) Left: representative OCR in Ova-EM *in vitro* (vehicle or CAY10585 treated OT-I WT and OT-I T/NIX^−/−^ cells). Right: fold change in long-chain fatty acid oxidation-linked OCR from left panel.\
(F) Fold change in short/branched-chain fatty acid oxidation linked OCR in Ova-EM formed *in vitro* (vehicle or CAY10585 treated OT-I WT and OT-I T/NIX^−/−^ cells).\
(G) Effect of loss of ACADSB on effector memory formation in OT-I WT and OT-I T/NIX^−/−^ cells transduced with LentiCRISPRv2 expressing sgRNA-control or sgRNA-ACADSB.\
(H) Intracellular ATP level in Ova-EM 30 days p.i. in WT and T/NIX^−/−^ mice.\
(I) Intracellular ATP in Ova-EM formed *in vitro* (vehicle or CAY10585 treated WT or T/NIX^−/−^ cells).\
(J) Intracellular ATP in Ova-EM formed *in vitro* (sgRNA-control or sgRNA-HIF1α transduced OT-I WT or OT-I T/NIX^−/−^ cells).\
Ova-EM from all mice within the same experimental group in (A)--(F) and (H)--(J) were pooled for analysis. Each point represents an individual independent experiment. Data are representative of two or more independent experiments (n = 4--9). Data were analyzed using two-tailed Student's t test (mean ± SEM). \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. ns, non-significant. See also [Figures S6](#SD1){ref-type="supplementary-material"} and [S7](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0007){#F6}

![Inhibiting HIF1α Accumulation Restores Effector Memory Formation in Antigen-Specific T/NIX^−/−^ CD8^+^ T cells\
(A) Representative plot showing percentage of Ova-EM formed *in vitro* from WT and T/NIX^−/−^ splenocytes (treated with vehicle or CAY10585 on day 4).\
(B) Mean frequency of Ova-EM from (A).\
(C) Effect of loss of HIF1α on effector memory formation. OT-I WT or OT-I T/NIX^−/−^ cells were transduced with LentiCRISPRv2 expressing sgRNA-HIF1α or sgRNA-control. Ova-EM from all mice within the same experimental group were combined. Each point represents an individual independent experiment.\
(D) Mean frequency of Ova-EM formed *in vitro* from WT and T/NIX^−/−^ splenocytes (treated with CAY10585 or CAY10585 and oligomycin).\
(E and F) IFN-Υ concentration in the spleen (E) and (F) viral titer in the brains of mice 48 h after infection with 10^6^ PFU of VSV-Ova. Naive C57/BL6J mice were injected with vehicle or CAY10585-treated WT or T/NIX^−/−^ cells, generated as in (A), followed by infection with VSV-Ova.\
Data in (A)--(D) are representative of two or more independent experiments (n = 5--8), and data in (E) and (F) are representative of four or five biological replicates per group. Data were analyzed by two-tailed Student's t test (mean ± SEM). \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. ns, non-significant. See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-1542962-f0008){#F7}
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KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                 SOURCE                                                    IDENTIFIER
  ----------------------------------------------------------------------------------- --------------------------------------------------------- -----------------------------------
  Antibodies                                                                                                                                    
  APC anti-mouse CD3 antibody                                                         Biolegend                                                 RRID: AB_2561456; Cat\#100236
  APC anti-mouse CD8a antibody                                                        Biolegend                                                 RRID: AB_312751; Cat\#100712
  Pacific Blue anti-mouse CD8a antibody                                               Biolegend                                                 RRID: AB_493425; Cat\#100725
  APC/Fire 750 anti-mouse CD8a antibody                                               Biolegend                                                 RRID: AB_2572113; Cat\#100766
  FITC anti-mouse/human CD44 antibody                                                 Biolegend                                                 RRID: AB_312957; Cat\#103006
  APC anti-mouse/human CD44 antibody                                                  Biolegend                                                 RRID: AB_312963; Cat\#103012
  APC/Fire 750 anti-mouse/human CD44 antibody                                         Biolegend                                                 RRID: AB_2616727; Cat\#103062
  PE/Cy7 anti-mouse CD62L antibody                                                    Biolegend                                                 RRID: AB_313103; Cat\#104418
  APC/Fire 750 anti-mouse CD62L antibody                                              Biolegend                                                 RRID: AB_2629772; Cat\#104450
  PerCP/Cy5.5 anti-mouse CD43 Activation-Associated Glycoform antibody                Biolegend                                                 RRID: AB_2286556; Cat\#121224
  PE anti-mouse CD127 (IL-7Rα) Antibody                                               Biolegend                                                 RRID: AB_1937251; Cat\#135010
  Anti-mouse CD127 PE-Cy5 50 ug antibody                                              Thermo Fisher Scientific                                  RRID: AB_468792; Cat\#15-1271-81
  FITC Mouse Anti-Mouse CD45.2                                                        BD PharMingen                                             RRID: AB_395041; Cat\#553772
  PE/Cy7 anti-mouse CD366 (Tim-3) Antibody                                            Biolegend                                                 RRID: AB_2632733; Cat\#134009
  Mouse TCF7/TCF1 Alexa Fluor® 647-conjugated Antibody                                R&D Systems                                               Cat\#FAB8224R
  PE/Cy7 anti-mouse/human KLRG1 (MAFA) antibody                                       Biolegend                                                 RRID: AB_2561736; Cat\#138416
  Brilliant Violet 605 anti-mouse CD185 (CXCR5) Antibody                              Biolegend                                                 RRID: AB_2562208; Cat\#145513
  PE/APC anti-mouse H-2K(b) SIINFEKL antibody (Ova_tetramer)                          Baylor College of Medicine MHC Tetramer Production Core   Cat\#16114
  FITC Annexin V                                                                      BD PharMingen                                             Cat\#51-65874X
  CD3e antibody                                                                       BD Biosciences                                            RRID: AB_394591; Cat\#553058
  Ultra-LEAF Purified anti-mouse CD3 antibody                                         Biolegend                                                 RRID: AB_2616673; Cat\#100359
  CD28 antibody                                                                       BD Biosciences                                            RRID: AB_394763; Cat\#553294
  Anti-mouse HIF-1 alpha Antibody                                                     Novus Biologicals                                         RRID: AB_10001045; Cat\#NB100-449
  Anti-mouse TFAM antibody                                                            Santa Cruz Biotechnology                                  RRID: AB_10610743; Cat\#sc-166965
  Anti-mouse ACADSB antibody                                                          Novus Biologicals                                         Cat\#NBP1-97833
  Chemicals, Peptides, and Recombinant Proteins                                                                                                 
  CAY10585                                                                            Cayman Chemical                                           Cat\#*934593-90-5*
  Ovalbumin                                                                           Sigma-Aldrich                                             Cat\#A7641
  N-Acetyl-L-Cysteine (NAC)                                                           Sigma-Aldrich                                             Cat\#A7250
  Hexadimethrine Bromide (polybrene)                                                  Sigma-Aldrich                                             Cat\#H9268
  Etomoxir                                                                            Sigma-Aldrich                                             Cat\#E1905
  FCCP                                                                                Sigma-Aldrich                                             Cat\#C2920
  Mouse IL-15                                                                         Biolegend                                                 Cat\#566304
  Critical Commercial Assays                                                                                                                    
  ATP Determination kit                                                               Molecular Probes                                          Cat\#A22066
  Mouse IL-2 ELISA MAX Standard                                                       Biolegend                                                 Cat\#431002
  Mouse IFNg ELISA MAX Standard                                                       Biolegend                                                 Cat\#430802
  Mouse TNF ELISA Set                                                                 BD Biosciences                                            Cat\#555268
  MitoSOX Red mitochondrial superoxide indicator                                      Invitrogen                                                Cat\#M36008
  Mitotracker Green FM                                                                Invitrogen                                                Cat\#M7514
  JC-1 dye                                                                            Invitrogen                                                Cat\#T3168
  Seahorse Xfe96 Flux assay kit                                                       Agilent Technologies                                      Cat\#101085-004
  Mouse DNA Damage Analysis Kit                                                       Detroit R&D                                               Cat\#DD2M
  Experimental Models: Cell Lines                                                                                                               
  NIH 3T3                                                                             CLS                                                       CVCL_0594
  293T                                                                                ATCC                                                      CVCL_0063
  BHK-21                                                                              CLS                                                       CVCL_1915
  Experimental Models: Organisms/Strains                                                                                                        
  Mouse: C57BL/6J                                                                     The Jackson Laboratory                                    IMSR_JAX:000664
  Mouse: NIX^f/f^                                                                     [@R30]                                                    N/A
  Mouse: B6.Cg-Tg(Lck-cre)548Jxm/J                                                    The Jackson Laboratory                                    IMSR_JAX:003802
  Mouse: C57BL/6-Tg(TcraTcrb)1100Mjb/J                                                The Jackson Laboratory                                    IMSR_JAX:003831
  Mouse: B6.SJL-Ptprc^a^ Pep3^b^/BoyJ, Pep Boy, B6 Cd45.1                             The Jackson Laboratory                                    IMSR_JAX:002014
  Oligonucleotides                                                                                                                              
  Primers for *18S*, see [Table S1](#SD1){ref-type="supplementary-material"}          This paper                                                N/A
  Primers for *Nix*, see [Table S1](#SD1){ref-type="supplementary-material"}          This paper                                                N/A
  Primers for *Bnip3*, see [Table S1](#SD1){ref-type="supplementary-material"}        This paper                                                N/A
  Primers for *Il-15rα*, see [Table S1](#SD1){ref-type="supplementary-material"}      This paper                                                N/A
  Primers for *Foxo1*, see [Table S1](#SD1){ref-type="supplementary-material"}        This paper                                                N/A
  Primers for *Tcf7*, see [Table S1](#SD1){ref-type="supplementary-material"}         This paper                                                N/A
  Primers for *Blimp-1*, see [Table S1](#SD1){ref-type="supplementary-material"}      This paper                                                N/A
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###### Highlights

-   NIX regulates mitophagy during effector memory formation in CD8^+^ T cells

-   NIX-mediated mitophagy prevents HIF1α accumulation during contraction phase

-   HIF1α alters metabolism from long-chain to short/branched-chain fatty acid oxidation

-   Optimal ATP generation is critical for effector memory formation in CD8^+^ T cells
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